OLINK HOLDING AB (PUBL) AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement March 29, 2021Deposit Agreement • March 17th, 2022 • Olink Holding AB (Publ) • Laboratory analytical instruments • New York
DEPOSIT AGREEMENT dated as of March 29, 2021 among OLINK HOLDING AB (PUBL), a public limited company incorporated under the laws of Sweden (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
Olink Holding AB (publ) 5,831,028 American Depositary Shares representing 5,831,028 Common Shares, quota value SEK 2.431906612470569 per share Underwriting AgreementUnderwriting Agreement • January 23rd, 2023 • Olink Holding AB (Publ) • Laboratory analytical instruments
Employment ContractEmployment Contract • October 31st, 2023 • Olink Holding AB (Publ) • Laboratory analytical instruments
Olink Proteomics AB 559046-8632 Uppsala (the “Company”) and Elias Berglund the “Employee”) have today entered into the following agreement regarding an employment at the Company.
PURCHASE AGREEMENT between THERMO FISHER SCIENTIFIC INC. and OLINK HOLDING AB (PUBL), dated as of October 17, 2023Purchase Agreement • October 18th, 2023 • Olink Holding AB (Publ) • Laboratory analytical instruments • Delaware
This PURCHASE AGREEMENT, dated as of October 17, 2023 (this “Agreement”), is entered into by and between Thermo Fisher Scientific Inc., a Delaware corporation (“Parent”), and Olink Holding AB (publ), a public limited liability company organized under the Laws of Sweden (the “Company”).
Lease by and between Cresset Grove LLC, Landlord, and Olink Proteomics, Inc., TenantWork Letter Agreement • March 3rd, 2021 • Olink Holding AB (Publ) • Laboratory analytical instruments • Massachusetts
OEM SUPPLY & DEVELOPMENT AGREEMENTDevelopment Agreement • March 17th, 2022 • Olink Holding AB (Publ) • Laboratory analytical instruments • California
This Agreement is made and entered into by and between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjölds väg 52B, SE-752 37 Uppsala, Sweden (hereinafter referred to as “Olink”), and Fluidigm Corporation, a Delaware corporation organized and existing under the laws of the United States of America, with its principal office at Two Tower Place, Suite 2000, South San Francisco, CA 94080 USA (hereinafter referred to as “Fluidigm”).
DocuSign Envelope ID: 530C9DF2-3B27-4865-9BFB-8BDC2388C913 AMENDMENT NO. 8 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 8 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its...Olink Holding AB (Publ) • March 25th, 2024 • Laboratory analytical instruments
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO THE INSTRUCTIONS TO FORM 20-F AND SEC RULES AND REGULATIONS. SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Development Agreement • March 17th, 2022 • Olink Holding AB (Publ) • Laboratory analytical instruments
Amendment No. 2 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752 37 Uppsala, Sweden ("Olink"), and Fluidigm Corporation, a Delaware corporation organized and existing under the laws of the United States of America, with its principal office at Two Tower Place, Suite 2000, South San Francisco, CA 94080 USA ("Fluidigm"), and together with Olink, the "Parties", and each, a "Party".
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 3rd, 2021 • Olink Holding AB (Publ) • Laboratory analytical instruments • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of the [DATE]1, 2021 by and among Olink Holding AB (publ), Reg. No. 559189-7755, a limited liability company incorporated under the laws of Sweden, or any of its assignees or successors (the “Company”), Knilo InvestCo AB, Reg. No. 559189-7748 , or any of its assignees or successors (the “Summa Investor”), each of the shareholders listed on Schedule B hereto (each an “Existing Shareholder”, collectively, the “Existing Shareholders” and, together with the Summa Investor(s), the “Existing Investors”), and any Person that becomes a party hereto pursuant to Section 2.15.
SHAREHOLDER AGREEMENT dated ___ March 2021 between the MAJORITY OWNER and the INDIVIDUALS and the HOLDING COMPANIES and the COMPANY regarding Instruments in the CompanyShareholder Agreement • March 18th, 2021 • Olink Holding AB (Publ) • Laboratory analytical instruments
CONTRACT OF EMPLOYMENT CONTRACT DATE: July 1st 2024Olink Holding AB (Publ) • July 5th, 2024 • Laboratory analytical instruments
For the avoidance of doubt any benefits not previously paid or varied under this Agreement and the new rate of Salary will commence from the Contract Date above.
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO THE INSTRUCTIONS TO FORM 20-F AND SEC RULES AND REGULATIONS. SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Development Agreement • March 17th, 2022 • Olink Holding AB (Publ) • Laboratory analytical instruments
Amendment No. 1 to OEM Supply & Development Agreement (the “Amendment”), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752 37 Uppsala, Sweden (“Olink”), and Fluidigm Corporation, a Delaware corporation organized and existing under the laws of the United States of America, with its principal office at Two Tower Place, Suite 2000, South San Francisco, CA 94080 USA (“Fluidigm”), and together with Olink, the “Parties”, and each, a “Party”.
REGISTRATION RIGHTS AGREEMENTAccession Agreement • March 17th, 2022 • Olink Holding AB (Publ) • Laboratory analytical instruments • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of the 25 March, 2021 by and among Olink Holding AB (publ), Reg. No. 559189-7755, a limited liability company incorporated under the laws of Sweden, or any of its assignees or successors (the “Company”), Knilo InvestCo AB, Reg. No. 559189-7748 , or any of its assignees or successors (the “Summa Investor”), each of the shareholders listed on Schedule A hereto (each an “Existing Shareholder”, collectively, the “Existing Shareholders” and, together with the Summa Investor(s), the “Existing Investors”), and any Person that becomes a party hereto pursuant to Section 2.15.
ContractEnglish Summary Lease Agreement • March 27th, 2023 • Olink Holding AB (Publ) • Laboratory analytical instruments
TRANSLATION FROM SWEDISH ORIGINAL 21 January 2021 Translation of Supplementary agreement No 6 to Lease No 54304-2031Lease Agreement • March 3rd, 2021 • Olink Holding AB (Publ) • Laboratory analytical instruments
Between the Parties the Lease Agreement is valid. The Tenant is expanding and needs more efficient workspace. Because of adaptations and streamlining of the lab/production area and a more flexible workflow, the Parties have this day made the following additions to the Lease Agreement:
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OEM SUPPLY AND...Supply and License Agreement • March 3rd, 2021 • Olink Holding AB (Publ) • Laboratory analytical instruments • Minnesota
This Manufacturing Supply Agreement, dated as of August 10, 2016 (the “Agreement”), is entered into by and between Bio-Techne Corp., a Minnesota corporation having its principal place of business at 614 McKinley Place NE (“Bio-Techne”), and Olink Proteomics AB, a Swedish company, registration no. 559046-8632, having an address at Dag Hammarskjölds väg 52B, SE-752 37 Uppsala, Sweden (“Buyer”, and together with Bio-Techne, the “Parties”, and each, a “Party”).
TRANSFER RESTRICTION AGREEMENTTransfer Restriction Agreement • October 18th, 2023 • Olink Holding AB (Publ) • Laboratory analytical instruments • Delaware
This TRANSFER RESTRICTION AGREEMENT (this “Agreement”), dated as of October 17, 2023, is entered into by and between Thermo Fisher Scientific Inc., a Delaware corporation (“Parent”) and each of the individuals or entities set forth on Schedule A (each, a “Shareholder”). All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Purchase Agreement (as defined below).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 18th, 2023 • Olink Holding AB (Publ) • Laboratory analytical instruments • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 17, 2023, is entered into by and among Thermo Fisher Scientific Inc., a Delaware corporation (“Parent”), each of the individuals or entities set forth on Schedule A (each, a “Shareholder”, including Jon Hindar, chairman of the Company Board, and Nicolas Roelofs, member of the Company Board (Jon Hindar and Nicolas Roelofs, together, the “Directors”)) and, solely with respect to Section 4.8, Summa Equity AB. All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Purchase Agreement (as defined below).
ContractOlink Holding AB (Publ) • October 31st, 2023 • Laboratory analytical instruments
Olink Holding AB, reg. no 559189-7755, Uppsala (the "Company") and Jon Heimer, personal identity number, Stockholm, (the "Executive"), have today concluded the following
DocuSign Envelope ID: 9E9E7F5C-C117-4B88-AA76-E4E4C42223EE AMENDMENT NO. 6 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 6 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its...Development Agreement • March 25th, 2024 • Olink Holding AB (Publ) • Laboratory analytical instruments
DocuSign Envelope ID: 55E92D28-CE56-49DA-97CC-5D28F616C5BE AMENDMENT NO. 7 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 7 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its...Development Agreement • March 25th, 2024 • Olink Holding AB (Publ) • Laboratory analytical instruments
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO THE INSTRUCTIONS TO FORM 20-F AND SEC RULES AND REGULATIONS. SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Development Agreement • March 17th, 2022 • Olink Holding AB (Publ) • Laboratory analytical instruments
Amendment No. 3 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752 37 Uppsala, Sweden ("Olink"), and Fluidigm Corporation, a Delaware corporation organized and existing under the laws of the United States of America, with its principal office at Two Tower Place, Suite 2000, South San Francisco, CA 94080 USA ("Fluidigm"), and together with Olink, the "Parties", and each, a "Party".
Olink Holding AB (publ) [●]American Depositary Shares representing [●]Common Shares, quota value SEK 2.431906612358040 per share Underwriting AgreementUnderwriting Agreement • July 12th, 2021 • Olink Holding AB (Publ) • Laboratory analytical instruments • New York
The shareholders of Olink Holding AB (publ), a Swedish public limited company (the “Company”) named in Schedule I hereto (the “Selling Stockholders”) propose, subject to the terms and conditions stated in this underwriting agreement (this “Agreement”), to sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 7,000,000 American Depositary Shares representing 7,000,000 Common Shares, quota value SEK 2.431906612358040 per share, of the Company (the “Common Shares”) and the Summa Selling Stockholders (defined below) proposes, subject to the terms and conditions stated in this Agreement, to sell to the Underwriters at the election of the Underwriters, up to 1,050,000 additional American Depositary Shares representing 1,050,000 Common Shares. The aggregate of 7,000,000 American Depositary Shares representing 7,000,000 Common Shares to be sold by the Selling Stockholders is herein called the “Firm ADSs”, and the aggregate of 1,050,000 American Depositary Sha
AMENDMENT NO. 4 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 4 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752...Development Agreement • March 25th, 2024 • Olink Holding AB (Publ) • Laboratory analytical instruments
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OEM SUPPLY...Oem Supply Agreement • March 3rd, 2021 • Olink Holding AB (Publ) • Laboratory analytical instruments • New York
This OEM Supply Agreement (this “Agreement”) is entered into as of December 29, 2016 (the “Effective Date”) by and between Fluidigm Corporation, a Delaware corporation with its principal place of business at 7000 Shoreline Court, Suite 100, South San Francisco, CA 94080 (“Fluidigm”), and Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjölds väg 52B, SE-752 37 Uppsala, Sweden (“Olink”).
SHAREHOLDER AGREEMENT datedShareholder Agreement • March 17th, 2022 • Olink Holding AB (Publ) • Laboratory analytical instruments
